Skip to main content
OpenTrials
Completed

NCT Number: NCT03766308

The Clinical Study of the Effect of Highland Barley Diet on Blood Glucose in Patients With Type 2 Diabetes Mellitus

The clinical study of the effect of highland barley diet on blood glucose in patients with type 2 diabetes mellitus

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology

Wuhan, Hubei, China

About this study

The clinical study of the effect of highland barley diet on blood glucose in patients with type 2 diabetes mellitus.

Approximately 40 patients will be enrolled in the study from China and randomized in a 1:1 ratio to one of the 2 treatment arms: highland barley diet + metformin; or +common diet metformin.

Study treatment will continue for 12 weeks. The primary efficacy measure is the change in HbA1c at 12 weeks. The study consists of 3 periods: a 1-week screening (period A), a 4-week run-in period (period B) and a 12-week treatment period (period C).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of informed consent
  • Type 2 diabetic patients (new diagnose )
  • HbA1c ≥7.0 % and < 9.0 % (HbA1c > 7.0 % and ≤ 8.0% at randomization)
  • Men and women (non-pregnant and using a medically approved birth-control method) aged ≥ 18 and ≤ 70 years
  • BMI ≥ 23 and ≤ 35 kg/m2

Exclusion criteria

  • Type 1 diabetes or other specific types of diabetes
  • Pregnancy, preparation for pregnancy, lactation and women of child-bearing age incapable of effective contraception methods
  • Uncooperative subject because of various reasons
  • Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST) > twice the upper limits of normal
  • Impairment of renal function, serum creatinine: ≥ 133mmol/L for female,≥ 135mmol/L for male
  • Serious chronic gastrointestinal diseases
  • Edema
  • Serious heart diseases, such as cardiac insufficiency (level III or more according to NYHA), acute coronary syndrome and old myocardial infraction
  • Blood pressure: Systolic blood pressure (SBP) ≥ 180mmHg and/or diastolic blood pressure (DBP) ≥ 110mmHg
  • White blood count (WBC) < 4.0×109/L or platelet count (PLT) < 90×109/L,or definite anemia (Hb:< 120g/L for male, < 110g/L for female), or other hematological diseases
  • Endocrine system diseases, such as hyperthyroidism and hypercortisolism
  • Experimental drug allergy or frequent hypoglycemia
  • Psychiatric disorders, drug or other substance abuse
  • Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy
  • Stressful situations such as surgery, serious trauma and so on
  • Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease
  • Combined use of drugs effecting glucose metabolism such as glucocorticoid Tumor, especially bladder tumor and/or family history of bladder tumor and/or long-term hematuria

Treatment and study plan

Highland Barley Diet

Dietary Supplement

Highland Barley Diet

ADA diet

Dietary Supplement

ADA diet

Primary outcomes

  1. HbA1c

    Time frame: from baseline to 12-week endpoint

    In the newly diagnosed type 2 diabetic patients, the absolute value of glycosylated hemoglobin from baseline to 12-week endpoints was compared between groups in the qingke diet group and the normal diet group.

Secondary outcomes

  1. The percentage of participants who achieved HbA1c ≤ 6.5% and < 7%

    Time frame: 12 weeks

    The percentage of participants who achieved HbA1c ≤ 6.5% and < 7%

  2. blood glucose

    Time frame: 6 weeks and 12weeks

    Fasting blood glucose

  3. Postprandial Blood Glucose

    Time frame: 6 weeks and 12weeks

    Postprandial blood glucose

  4. 7 point self-monitoring blood sugar

    Time frame: from baseline to 6 and 12 weeks

    7 point self-monitoring blood sugar

  5. blood lipid

    Time frame: from baseline to 6 and 12 weeks

    blood lipid

  6. uric acid

    Time frame: from baseline to 6 and 12 weeks

    uric acid

  7. Insulin resistance index

    Time frame: 0weeks and 12weeks

    Insulin resistance index

  8. Beta cell function index of islet

    Time frame: 0weeks and 12weeks

    Beta cell function index of islet

  9. Change in body weight

    Time frame: from baseline to 12 weeks

    Change in body weight

  10. Change in Waist circumference

    Time frame: from baseline to 12 weeks

    Change in Waist circumference

Sponsors and collaborators

Lead sponsor

Xuefeng Yu

Other

Registry information

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Dec 6, 2018
Registry last updated
Sep 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.